December 1, 2015
September’s announcement by Carl Zeiss Meditec that its AngioPlex OCT angiography technology had received 510(k) clearance from the FDA set the stage for other systems to likely also soon become commercialized in the U.S. The technology allows extreme close-up imaging of the retinal vasculature for assessing retinal vascular diseases and holds potential for guiding treatment decisions and monitoring patient responses to therapy.
“Over the past 20 years, OCT has developed rapidly as a ‘noninvasive’ method of imaging for medical diagnosis and defining activity criteria, such as intra/subretinal fluid, hyper-reflective dots and dense intraretinal areas,” Gabriel J. Coscas, MD, emeritus professor of ophthalmology at the University of Paris XII in Créteil, France, said. But over the past 2 years, it was found that additional information useful for treatment decisions can now be gained with OCT angiography (OCTA).